RxDoctor Payments Data

Brian Briscoe, MD

Psychiatry · Louisville, KYNPI 1912045212

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,500 of the $6,503 with a category attached, or 84.6%. Tris Pharma Inc accounts for 88.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $5,297 and has fallen 89.8% since, to $538 in 2023.

$6,503in general payments, 2019–2025

Across 61 payments — averaging $106.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tris Pharma Inc$6K
  • AbbVie$140
  • Otsuka America Pharmaceutical, Inc.$92
  • Lundbeck LLC$77
  • Sunovion Pharmaceuticals Inc.$73
  • Johnson & Johnson$71
  • plus $299 from 11 others

What the payments were for

  • Speaking & faculty fees$5,50085%
  • Food & beverage$1,00315%

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,503 in reported general payments places this provider in the 85th percentile of 348 psychiatry providers in Kentucky.

See all psychiatry providers in Kentucky

Medicare billing

Part B allowed, 2024
$8,697
Medicare patients
35
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole11$15,929
Lurasidone Hcl16$4,016
Aripiprazole24$968
Divalproex Sodium ErDivalproex Sodium14$839
Ziprasidone Hcl11$585
Quetiapine Fumarate25$396
Duloxetine Hcl20$301
Alprazolam ErAlprazolam14$254
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$246
Lamotrigine17$241
Bupropion XlBupropion Hcl16$221
Methylphenidate Hcl12$189
Trazodone Hcl16$165
Clonazepam24$144
Gabapentin18$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$92$15,92911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 348 psychiatry providers in Kentucky.

Other psychiatry in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →